Figure 6.
Estimated disease variance explained by 27 common risk genomic variants reported in 19 AMD loci. Relative risks were estimated using the independent risk effects of each variant conditioned on all other variants, assuming disease prevalences of 2.8%, 5.6%, and 10.9%, which correspond to the predicted prevalences of late AMD in European populations at ages 75, 80, and 85 years, respectively (82). Reference 93 describes the methods applied to measure the variance of the disease. Abbreviation: SNP, single-nucleotide polymorphism. favors combinatorial and synergistic mechanisms involving gene or pathway interactions leading to AMD pathogenesis.